|
시장보고서
상품코드
2128963
유전성 혈관부종 치료제 시장 : 약제 클래스별, 치료법별, 투여 경로별, 최종 사용자별, 국가별, 지역별 - 업계 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)Hereditary Angioedema Therapeutics Market, By Drug Class, By Treatment Type, By Route of Administration, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033 |
||||||
유전성 혈관부종 치료제 시장 규모는 2025년에 34억 9,060만 달러로 평가되었고, 2026-2033년 CAGR 10.6%로 성장할 전망입니다.
유전성 혈관부종(HAE) 치료제 시장은 칼리크레인-키닌 계통의 조절 이상을 특징으로 하는 희귀 유전성 질환인 유전성 혈관부종(HAE)으로 인한 재발성 부종을 예방하거나 치료하는 약제로 구성되어 있습니다. C1 에스테라제 억제제, 브라디키닌 B2 수용체 길항제, 칼리크레인 억제제를 비롯해, 보다 새롭고 특이성이 높은 생물학적 제제 등 다양한 유형의 치료법이 이용 가능합니다. 이러한 약물은 발작 시 투여되는 ‘온디맨드 치료’와 발작 빈도를 줄이는 ‘예방 치료’로 분류됩니다. 시장에서는 표적 치료와 피하 투여 및 경구 투여를 포함한 편의성이 높은 투여법에 대한 관심이 높아지고 있습니다.
유전성 혈관부종 치료제 시장 : 시장 역학
HAE 발작에 대한 효과적인 장기 예방 및 신속한 치료에 대한 수요 증가
생명을 위협할 수 있는 발작을 예방하고 급성기 HAE를 치료해야 한다는 임상적 필요성이 높아지면서, 유전성 혈관부종(HAE) 치료제 시장의 성장을 이끄는 중요한 요인이 되고 있습니다. HAE에서는 피부, 소화관, 상기도의 부종이 반복적으로 발생할 수 있습니다. 생명을 위협할 수 있는 합병증으로는 후두 발작이 있습니다. 이 질환은 만성적이고 재발성이기 때문에 환자는 필요 시 치료 외에도 만성적인 치료 및 예방이 필요할 수 있습니다. HAE는 인구 5만 명당 약 1명의 비율로 발병하는 것으로 알려져 있으며, 분명히 특별한 관리가 필요한 희귀질환입니다.
또한, 특정 경로를 표적으로 하는 의약품도 치료 분야에서 주목받고 있습니다. C1 에스테라제 억제제는 결핍된 C1-INH를 보충하거나 대체하는 데 사용되며, 칼리크레인 억제제와 브라디키닌 수용체 길항제는 부종을 유발하는 하류 성분을 표적으로 사용됩니다. 가정 투여나 경구 투여가 점점 더 선호되는 추세에 따라, 경구 제제, 피하 투여 제제 및 프리필드 디바이스 제제의 개발이 더욱 촉진되고 있습니다.
유전성 혈관부종 치료제 시장 : 시장 세분화 분석
세계 유전성 혈관부종 치료제 시장은 약물 분류, 치료 유형, 투여 경로, 최종 사용자 및 지역을 기준으로 세분화됩니다.
약제 분류별로 보면, 혈장 칼리크레인은 HAE의 염증과 관련된 브라디키닌 경로의 주요 구성 요소로 간주되므로, 칼리크레인 억제제가 시장의 주요 구성 요소가 될 것으로 예측됩니다. 이 범주에는 HAE 발작 및 예방을 위한 경구용 약물과 주사제가 포함됩니다. FDA는 2025년 7월, 급성 HAE 발작에 대한 경구용 혈장 칼리크레인 억제제인 EKTERLY(세베트랄스타트)를 승인했습니다. 이 약물은 20개국 66개 기관에서 110명의 피험자를 대상으로 한 KONFIDENT 임상시험 결과를 바탕으로 승인되었습니다. 이 치료제는 발작을 인지한 직후 경구로 복용하는 정제로, 필요 시 치료(on-demand therapy)에서 경구 칼리크레인 억제의 중요성을 부각시키고 있습니다.
예방 요법의 중요성은 점점 더 커지고 있습니다. 이는 환자와 의사가 단순한 응급 치료에 그치지 않고, 발작 빈도의 지속적인 감소를 점점 더 요구하고 있기 때문입니다. 예를 들어, 2025년 6월 FDA는 HAE 발작 예방을 목적으로 ‘ANDEMBRY(가라다시맙)’를 승인했습니다. 이 치료법은 초기 투여 후월1회 피하 주사로 투여됩니다.
유전성 혈관부종 치료제 시장 - 지역별 분석
북미의 유전성 혈관부종 치료제 시장은 희귀질환에 대한 전문적인 서비스, 충실한 보험 급여 및 치료 관리, 임상시험, 그리고 새로운 치료법에 대한 규제 당국의 신속한 승인이 실현되고 있어 가장 발전된 지역 중 하나가 되었습니다. 2025년에는 ‘ANDEMBRY’(6월),‘EKTERLY’(7월), ‘DAWNZERA’(8월) 등 몇 가지 주요 HAE 치료제가 미국 FDA의 승인을 받았습니다. 이러한 승인을 통해 단일클론 항체를 이용한 예방 요법, 경구용 온디맨드 요법, 그리고 RNA를 표적으로 하는 예방 요법과 같은 새로운 치료 선택지가 시장에 도입되었습니다.
유럽 또한 희귀질환에 대한 치료 인프라가 충분히 갖춰져 있고, 희귀질환 면역학 및 알레르기 전문의에게 쉽게 접근할 수 있다는 점에서 중요한 시장으로 자리 잡고 있습니다. 예를 들어, CSL사는 호주와 영국에서 규제 당국의 승인을 획득했다고 발표했으며, 유럽집행위원회는 2025년 2월 11일에 ‘ANDEMBRY’를 승인했습니다. HAE 예방 요법으로서, 제XIIa 인자 표적형월1회 투여 요법의 유럽 내 사용이 승인되었습니다.
목차
제1장 유전성 혈관부종 치료제 시장 개요
제2장 주요 요약
제3장 유전성 혈관부종 치료제 주요 시장 동향
제4장 유전성 혈관부종 치료제 산업 분석
제5장 유전성 혈관부종 치료제 시장 : 높아지는 지정학적 긴장의 영향
제6장 유전성 혈관부종 치료제 시장 구도
제7장 유전성 혈관부종 치료제 시장 : 약제 클래스별
제8장 유전성 혈관부종 치료제 시장 : 치료 유형별
제9장 유전성 혈관부종 치료제 시장 : 투여 경로별
제10장 유전성 혈관부종 치료제 시장 : 최종 사용자별
제11장 유전성 혈관부종 치료제 시장 : 지역별
제12장 주요 벤더 분석 : 유전성 혈관부종 치료제 산업
제13장 AnalystView 전방위 전망
AJY 26.09.17Hereditary Angioedema Therapeutics Market size was valued at US$ 3,490.6 Million in 2025, expanding at a CAGR of 10.6% from 2026 to 2033.
The Hereditary Angioedema (HAE) Therapeutics Market comprises drugs that prevent or cure recurring swellings from hereditary angioedema (HAE), which is a rare inherited condition marked by the dysregulation of the kallikrein-kinin system. There are different kinds of treatment that can be used including C1-esterase inhibitors, bradykinin B2 receptor antagonists, and kallikrein inhibitors as well as other newer, more specific biological treatments. The drugs may be categorized as on-demand treatment, which is applied during an attack of the disease, or prophylactic, which decreases the frequency of attacks. The market is increasingly focusing on targeted treatment and convenient administration of the drug including subcutaneous and oral therapy.
Hereditary Angioedema Therapeutics Market- Market Dynamics
Rising Need for Effective Long-Term Prevention and Rapid Treatment of HAE Attacks
The increasing clinical need for preventing attacks that might become life-threatening and for treating HAE in acute conditions is the important reason for Hereditary Angioedema Therapeutics Market growth. The swelling of the skin, gastrointestinal tract, and upper respiratory passage may happen repeatedly in HAE. The complication that might become life-threatening is laryngeal attacks. The disease is chronic and recurrent, so patients might need chronic treatment and prevention as well as on-demand treatment. HAE is thought to affect about 1 in every 50,000 people, clearly a rare disease that needs additional care.
Pathway-specific medicines are also becoming the focus of the treatment environment. C1-esterase inhibitors are used to replace or replace a defective C1-INH, kallikrein inhibitors and bradykinin receptor antagonists are used to target downstream components that cause swelling. Increasingly frequent preference for home dosing and oral administration further drives development of oral and subcutaneous and prefilled-device formulations.
Hereditary Angioedema Therapeutics Market- Segmentation Analysis:
The Global Hereditary Angioedema Therapeutics Market is segmented on the basis of Drug Class, Treatment Type, Route of Administration, End User, and Region.
Drug Class shows that Kallikrein Inhibitors are expected to be a major contributor since plasma kallikrein is considered a major part of the bradykinin pathway associated with HAE inflammation. The category includes oral and injectable treatment for HAE attacks and prophylaxis. FDA has approved EKTERLY (sebetralstat), which is an oral plasma kallikrein inhibitor for acute HAE attacks in July 2025. The drug received its approval based on the results of the KONFIDENT study involving 110 participants across 66 sites in 20 countries. The treatment comes as a tablet to take orally when an attack is first noticed, thus highlighting the importance of oral kallikrein inhibition in on-demand treatment.
Prophylaxis Treatment is becoming more relevant because patients and physicians are increasingly looking for a permanent decrease in attack frequency, not just emergency treatment. In June 2025, for instance, FDA approved ANDEMBRY (garadacimab) specifically for the prevention of HAE attacks, a treatment that is administered subcutaneously once a month after a loading dose.
Hereditary Angioedema Therapeutics Market- Geographical Insights
The Hereditary Angioedema therapeutics market in North America is one of the most advanced regions as it has witnessed specialized services for rare diseases, robust reimbursement and treatment care, clinical trials, and quick regulatory acceptance of novel therapies. In 2025, several key HAE drugs were approved by the U.S. FDA, such as ANDEMBRY (June), EKTERLY (July), and DAWNZERA (August). These approvals brought additional treatment options to the market for monoclonal-antibody prophylaxis, oral on-demand therapy and RNA-targeted prophylaxis.
The European region is also a key market due to its well-developed treatment infrastructure for rare diseases and access to rare disease immunology and allergy specialists. For instance, CSL said it had secured regulatory approvals in Australia and UK, with the European Commission approving ANDEMBRY on February 11, 2025. European authorization was granted for use of a Factor XIIa-targeting once-monthly therapy for HAE prophylaxis.
Hereditary Angioedema Therapeutics Market- Competitive Landscape:
The Hereditary Angioedema Therapeutics Market features intense competition from plasma derived product manufacturers and biotech firms developing drugs for targeted kallikrein, bradykinin, Factor XIIa, and RNA therapeutics. Some of the major market players include CSL Behring, Takeda Pharmaceutical Company, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Ionis Pharmaceuticals, Pharming Group, Intellia Therapeutics, and CENTOGENE. The focus of the competition has been shifting to the number of attacks reduced, how quickly to respond, how long the interval between doses and how easy it is to administer at home.
Recent Developments:
In July 2026, Pharvaris announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for deucrictibant immediate-release capsules to treat a hereditary angioedema attack when needed. The application included favorable clinical results showing fast onset, long duration of response and a favourable safety profile. April 23, 2027 was the FDA's PDUFA action date.
In December 2025, GENESIS Pharma signed an exclusive partnership agreement with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema (HAE) in Central and Eastern Europe. GENESIS Pharma has agreed to be the exclusive distributor and commercialiser of donidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Poland, Romania, Slovakia and Slovenia.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Takeda Pharmaceutical Company Limited
- CSL Behring
- Pharming Group N.V.
- BioCryst Pharmaceuticals, Inc.
- Chiesi Group
- Ionis Pharmaceuticals, Inc.
- Pharvaris N.V.
- Sanofi
- Arrowhead Pharmaceuticals, Inc.
- Intellia Therapeutics, Inc.
- Grifols, S.A.
- Octapharma AG
- Swedish Orphan Biovitrum (Sobi)
- Kedrion Biopharma Inc.
- Adverum Biotechnologies, Inc.
- Attune Pharmaceuticals, Inc.
- BioMarin Pharmaceutical Inc.
- Regeneron Pharmaceuticals, Inc.
- ADARx Pharmaceuticals, Inc.
- Others
GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- C1-Esterase Inhibitors
- Plasma Kallikrein Inhibitors
- Bradykinin B2 Receptor Antagonists
- Factor XIIa Inhibitors
- RNA-Targeted Therapies
- Others
GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020 - 2033
- On-Demand Treatment
- Prophylaxis Treatment
GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033
- Intravenous
- Subcutaneous
- Oral
GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Table of Contents
1. Hereditary Angioedema Therapeutics Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.2. Competitive Insights
3. Hereditary Angioedema Therapeutics Key Market Trends
- 3.1. Hereditary Angioedema Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Hereditary Angioedema Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Hereditary Angioedema Therapeutics Market Opportunities
- 3.4. Hereditary Angioedema Therapeutics Market Future Trends
4. Hereditary Angioedema Therapeutics Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Hereditary Angioedema Therapeutics Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Hereditary Angioedema Therapeutics Market Landscape
- 6.1. Hereditary Angioedema Therapeutics Market Share Analysis, 2025
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Hereditary Angioedema Therapeutics Market - By Drug Class
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
- 7.1.2. C1-Esterase Inhibitors
- 7.1.3. Plasma Kallikrein Inhibitors
- 7.1.4. Bradykinin B2 Receptor Antagonists
- 7.1.5. Factor XIIa Inhibitors
- 7.1.6. RNA-Targeted Therapies
- 7.1.7. Others
8. Hereditary Angioedema Therapeutics Market - By Treatment Type
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
- 8.1.2. On-Demand Treatment
- 8.1.3. Prophylaxis Treatment
9. Hereditary Angioedema Therapeutics Market - By Route of Administration
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
- 9.1.2. Intravenous
- 9.1.3. Subcutaneous
- 9.1.4. Oral
10. Hereditary Angioedema Therapeutics Market - By End User
- 10.1. Overview
- 10.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
- 10.1.2. Hospitals
- 10.1.3. Specialty Clinics
- 10.1.4. Home Healthcare
- 10.1.5. Others
11. Hereditary Angioedema Therapeutics Market- By Geography
- 11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
- 11.2. North America
- 11.2.1. Overview
- 11.2.2. Hereditary Angioedema Therapeutics Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.2.8. U.S.
- 11.2.8.1. Overview
- 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.2.8.4. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.2.9. Canada
- 11.2.9.1. Overview
- 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.2.9.4. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3. Europe
- 11.3.1. Overview
- 11.3.2. Hereditary Angioedema Therapeutics Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.8. Germany
- 11.3.8.1. Overview
- 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.8.4. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.9. UK
- 11.3.9.1. Overview
- 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.9.3. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.9.4. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.10. France
- 11.3.10.1. Overview
- 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.10.3. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.10.4. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.11. Italy
- 11.3.11.1. Overview
- 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.11.3. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.11.4. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.12. Spain
- 11.3.12.1. Overview
- 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.12.3. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.12.4. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.13. The Netherlands
- 11.3.13.1. Overview
- 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.13.3. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.13.4. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.14. Sweden
- 11.3.14.1. Overview
- 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.14.4. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.15. Russia
- 11.3.15.1. Overview
- 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.15.3. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.15.4. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.16. Poland
- 11.3.16.1. Overview
- 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.16.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.16.4. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.17. Denmark
- 11.3.17.1. Overview
- 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.17.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.17.4. Denmark Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.17.5. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.17.6. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.3.18. Rest of Europe
- 11.3.18.1. Overview
- 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.3.18.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.18.4. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.18.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.3.18.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Hereditary Angioedema Therapeutics Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.8. China
- 11.4.8.1. Overview
- 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.8.3. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.8.4. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.9. India
- 11.4.9.1. Overview
- 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.9.3. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.9.4. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.10. Japan
- 11.4.10.1. Overview
- 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.10.4. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.11. South Korea
- 11.4.11.1. Overview
- 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.11.4. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.12. Australia
- 11.4.12.1. Overview
- 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.12.4. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.13. Indonesia
- 11.4.13.1. Overview
- 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.13.4. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.14. Thailand
- 11.4.14.1. Overview
- 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.14.4. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.15. Philippines
- 11.4.15.1. Overview
- 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.15.4. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.16. Taiwan
- 11.4.16.1. Overview
- 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.16.3. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.16.4. Taiwan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.16.5. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.16.6. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.17. Vietnam
- 11.4.17.1. Overview
- 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.17.3. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.17.4. Vietnam Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.17.5. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.17.6. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.4.18. Rest of APAC
- 11.4.18.1. Overview
- 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.4.18.3. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.18.4. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.18.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.4.18.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Hereditary Angioedema Therapeutics Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.5.8. Brazil
- 11.5.8.1. Overview
- 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.5.8.4. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.5.9. Mexico
- 11.5.9.1. Overview
- 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.5.9.4. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.5.10. Argentina
- 11.5.10.1. Overview
- 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.5.10.4. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.5.11. Colombia
- 11.5.11.1. Overview
- 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.5.11.4. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.5.12. Rest of LATAM
- 11.5.12.1. Overview
- 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Hereditary Angioedema Therapeutics Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.8. Saudi Arabia
- 11.6.8.1. Overview
- 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.9. United Arab Emirates
- 11.6.9.1. Overview
- 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.10. Israel
- 11.6.10.1. Overview
- 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.10.4. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.11. Turkey
- 11.6.11.1. Overview
- 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.11.4. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.12. Algeria
- 11.6.12.1. Overview
- 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.12.4. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.13. Egypt
- 11.6.13.1. Overview
- 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.13.4. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.14. Iran
- 11.6.14.1. Overview
- 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.14.3. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.14.4. Iran Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.6.14.5. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.14.6. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.15. Qatar
- 11.6.15.1. Overview
- 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.15.3. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.15.4. Qatar Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.6.15.5. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.15.6. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 11.6.16. Rest of MEA
- 11.6.16.1. Overview
- 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 11.6.16.3. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.16.4. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.6.16.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 11.6.16.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Hereditary Angioedema Therapeutics Industry
- 12.1. Competitive Benchmarking
- 12.1.1. Competitive Dashboard
- 12.1.2. Competitive Positioning
- 12.2. Company Profiles
- 12.2.1. Takeda Pharmaceutical Company Limited
- 12.2.2. CSL Behring
- 12.2.3. Pharming Group N.V.
- 12.2.4. BioCryst Pharmaceuticals, Inc.
- 12.2.5. Chiesi Group
- 12.2.6. Ionis Pharmaceuticals, Inc.
- 12.2.7. Pharvaris N.V.
- 12.2.8. Sanofi
- 12.2.9. Arrowhead Pharmaceuticals, Inc.
- 12.2.10. Intellia Therapeutics, Inc.
- 12.2.11. Grifols, S.A.
- 12.2.12. Octapharma AG
- 12.2.13. Swedish Orphan Biovitrum (Sobi)
- 12.2.14. Kedrion Biopharma Inc.
- 12.2.15. Adverum Biotechnologies, Inc.
- 12.2.16. Attune Pharmaceuticals, Inc.
- 12.2.17. BioMarin Pharmaceutical Inc.
- 12.2.18. Regeneron Pharmaceuticals, Inc.
- 12.2.19. ADARx Pharmaceuticals, Inc.
- 12.2.20. Others
13. 360 Degree AnalystView
14. Appendix
- 14.1. Research Methodology
- 14.2. References
- 14.3. Abbreviations
- 14.4. Disclaimer
- 14.5. Contact Us
